Proactiveinvestors recommends
Additional Information
Market: ASX
Sector: Healthcare, Equipment & Services
EPIC: IPD
Latest Price: A$0.54  (0,00%)
52-week High: A$0.84
52-week Low: A$0.44
Market Cap: A$84.40M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Impedimed Limited
www.impedimed.com
ImpediMed Limited is an Australia-based company engaged in the development, manufacture and sale of bioimpedance instruments to direct customers and distributors. The Company’s products include ImpediVET, Imp DF50, Imp SFB7, Imp XCA, ImpSFB7 and electrodes. ImpediMed is focused on becoming a supplier of non-invasive medical devices to two under-served healthcare markets, assessment of individuals at risk of secondary lymphoedema, where ImpediMed’s products can help guide earlier treatment that has the potential to prevent the condition from progressing and monitoring of body hydration and composition, where ImpediMed plans to set a new standard in accuracy for point-of-care analysis. On October 1, 2007, the Company completed the acquisition of XITRON Technologies, Inc (Xitron). Xitron specializes in the manufacture and sale of power test and measurement devices.
Full Impedimed Limited profile here
Pdf

More kudos for ImpediMed BIS device for early detection of lymphedema

24th Nov 2009, 10:50 am

A University of Sydney study has found that ImpediMed's (ASX: IPD) Bioimpedance Spectroscopy (BIS) device is the most suitable for early detection and monitoring of lymphedema.

The share price of ImpediMed moved higher to $0.85 on the news.

The study's findings by researchers at the University of Sydney‟s Breast Cancer Research Group were published this month in the journal Cancer Investigation - found that "BIS is the only measurement method specific to extracellular fluid, ideally suited for early detection and monitoring of lymphedema."

ImpediMed CEO Greg Brown said "this latest study adds weight to the debate presently being held around the globe about the need for standardised objective metrics driving evidence based medicine."

"ImpediMed is very focussed on changing the care model for lymphoedema management in cancer patients from a reactive to a prospective one, he said."

"If lymphoedema can be detected early, progression to the irreversible stages of the condition may be prevented, affording the patient a far better quality of life. We are pleased to be able to offer our L-Dex® U400 device to clinicians to aid them in the early clinical assessment of lymphoedema."

The study was a comparison of physical measurement methods and self report in the assessment of breast cancer-related arm lymphoedema.

It observed that the results from physical measurement methods other than BIS may be confounded by changes not related to lymphoedema such as muscle and fat. Therefore, early lymphoedema build up may go undetected when using these measurement methods.

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.